Published in J Clin Oncol on May 01, 2001
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant (2007) 1.84
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol (2008) 1.57
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol (2008) 1.14
Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn (2009) 0.85
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood (2012) 0.84
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples. BMC Med Genomics (2012) 0.83
Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo. J Mol Diagn (2004) 0.83
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia (2016) 0.78
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. Semin Hematol (2015) 0.77
Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia. Rep Biochem Mol Biol (2014) 0.77
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. Stem Cells Int (2016) 0.75
Incidence of Common Fusion Transcripts in Adult and Pediatric Acute Myeloid Leukemia (AML) Cases: Experience of a Tertiary Care Research institute. Mediterr J Hematol Infect Dis (2012) 0.75
Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med (2007) 0.75
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
A gene map of the human genome. Science (1996) 14.32
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Career preferences of doctors who qualified in the United Kingdom in 1993 compared with those of doctors qualifying in 1974, 1977, 1980, and 1983. BMJ (1996) 12.00
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia (2007) 8.34
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of ribulose-1,5-bisphosphate carboxylase. EMBO J (1984) 6.53
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A (1997) 5.61
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet (1999) 5.09
Twenty five years of case finding and audit in a socially deprived community. BMJ (1991) 4.89
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Interleukin 15: biology and relevance to human disease. Blood (2001) 4.47
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet (1997) 4.29
Career destinations in 1994 of United Kingdom medical graduates of 1983: results of a questionnaire survey. BMJ (1996) 4.27
Genetic linkage between hereditary hemochromatosis and HLA. Am J Hum Genet (1979) 3.96
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res (2001) 3.66
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Isolation and identification of methanogen-specific DNA from blanket bog peat by PCR amplification and sequence analysis. Appl Environ Microbiol (1996) 3.47
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost (1993) 3.12
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A (2001) 3.01
Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med (1995) 2.96
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med (2001) 2.96
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab (2000) 2.68
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood (1996) 2.62
Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Mol Cell Biol (1987) 2.59
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection. Am J Clin Pathol (1999) 2.55
ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst (1992) 2.54
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction (1998) 2.41
Paracentric inversions in humans: a review of 446 paracentric inversions with presentation of 120 new cases. Am J Med Genet (1995) 2.39
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
Extraction and high-performance liquid chromatographic method for the determination of microcystins in raw and treated waters. Analyst (1994) 2.27
Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med (1975) 2.25
Pharmacy beyond the dispensary: general practitioners' views. BMJ (1992) 2.22
Parental perceptions of overweight in 3-5 y olds. Int J Obes (Lond) (2005) 2.21
Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro. Transfusion (1992) 2.21
Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab (1995) 2.20
Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec (2001) 2.18
Role of Donnan equilibrium in the resting potentials in glycerol-extracted muscle. Am J Physiol (1971) 2.16
Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology (2001) 2.13
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
Difference in effects of end-plate potentials between procaine and lidocaine as revealed by voltage-clamp experiments. J Neurophysiol (1971) 2.08
Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet (1986) 2.07
Perforation of the bladder: a complication of long-dwelling Foley catheter. J Urol (1973) 2.05
A case revisited: recent presentation of incontinentia pigmenti in association with a previously reported X;autosome translocation. Am J Med Genet (1997) 2.05
Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab (2000) 1.99
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood (1989) 1.98
A factor analysis of the Klein sexual orientation grid in two disparate samples. Arch Sex Behav (1993) 1.98
Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ (1997) 1.96
Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab (1971) 1.96
Effects on the right ventricle, pulmonary vasculature, and carotid bodies of the rat of exposure to, and recovery from, simulated high altitude. Thorax (1973) 1.95
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood (1993) 1.94
Obstructive appendicopathy: a disease or a congenital entity? J Clin Pathol (2008) 1.93
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science (1986) 1.91
Comparison of prescribing unit with index including both age and sex in assessing general practice prescribing costs. BMJ (1993) 1.90
Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence. J Immunol (1995) 1.88
Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med (1983) 1.86
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Role of cloned carotenoid genes expressed in Escherichia coli in protecting against inactivation by near-UV light and specific phototoxic molecules. J Bacteriol (1988) 1.84
Response to thyrotropin releasing hormone (TRH) in normal man. J Clin Endocrinol Metab (1972) 1.82
Screen detected high blood pressure under 40: a general practice population followed up for 21 years. BMJ (1993) 1.82